Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 9/20 | 1.00 |
| ▸ | MET | P08581 | 6/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | SRC | P12931 | 3/20 | 0.51 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | KIT | P10721 | 3/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.51 |
| ▸ | NEK2 | P51955 | 2/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31016300 | 1.00 | KDR (1.00) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL31678823 | 1.00 | KDR (1.00) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL93713 | 1.00 | KDR (1.00) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL29394393 | 1.00 | KDR (1.00) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL12627744 | 0.88 | KDR (0.79) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL18999612 | 0.88 | KDR (0.79) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL12627743 | 0.88 | MET (0.78) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL12627741 | 0.88 | KDR (0.78) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL145435 | 0.86 | KDR (0.76) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL12627745 | 0.86 | KDR (0.75) | KDRFGFR1METPTK2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | claimed |
| EP-2976354-A1 | STAPLING eIF4E INTERACTING PEPTIDES | Agency For Science, Technology And Research (SG) | 2016-01-27 | — | — | EP | claimed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | claimed |
| US-20140348819-A1 | Methods of Treating Cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-11-27 | — | — | US | claimed |
| WO-2014149001-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-09-25 | — | — | WO | claimed |
| US-8729043-B2 | Anti-Met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products | METHERESIS TRANSLATIONAL RESEARCH S.A. (CH) | 2014-05-20 | — | — | US | claimed |
| US-20120134996-A1 | Anti-met monoclonal antibody, fragments and vectors thereof , for the treatment of tumors and corresponding products | METHERESIS TRANSLATIONAL RESEARCH SA, (CH) | 2012-05-31 | — | — | US | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| EP-1981981-B1 | ANTI-MET MONOCLONAL ANTIBODY, FRAGMENTS AND VECTORS THEREOF, FOR THE TREATMENT OF TUMORS AND CORRESPONDING PRODUCTS | METHERESIS TRANSLATIONAL RES SA (CH) | 2011-06-29 | — | — | EP | claimed |
| US-20090285807-A1 | Anti-Met Monoclonal Antibody, Fragments and Vectors Thereof, for the Treatment of Tumors and Corresponding Products | Pierre Fabre Médicament (FR) | 2009-11-19 | — | — | US | claimed |
| WO-2009092052-A2 | METHODS AND COMPOSITIONS FOR TREATING POLYPS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2009-07-23 | — | — | WO | claimed |
| WO-2026102277-A1 | COMBINATION THERAPIES COMPRISING IKZF2 DEGRADER COMPOUNDS | Plexium, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4730355-A1 | TYPING SYSTEM AND METHOD FOR HR-POSITIVE/HER2-NEGATIVE BREAST CANCER | Lumitype Medical (Huzhou) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-20090285807-A1 | Anti-Met Monoclonal Antibody, Fragments and Vectors Thereof, for the Treatment of Tumors and Corresponding Products | Pierre Fabre Médicament (FR) | 2009-11-19 | — | — | US | disclosed |
| WO-2009111529-A2 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009092052-A2 | METHODS AND COMPOSITIONS FOR TREATING POLYPS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008113013-A2 | C-MET MUTATIONS AND USES THEREOF | UNIVERSITY OF CHICAGO (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2005082411-A1 | METHOD OF TREATING ABNORMAL CELL GROWTH USING C-MET AND-TOR INHIBITORS | SUGEN, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | KDR 3515/4885FGFR1 2064/4885MET 1078/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | KDR 3638/4885FGFR1 3273/4885MET 2104/4885 |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | KDR 3718/4885FGFR1 3579/4885MET 4489/4885 |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | TP53, MDM4, MDM2 | KDR 1025/4885FGFR1 1156/4885MET 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.